Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2

Akio Hiraki, Katsuyuki Kiura, Hiromichi Yamane, Naoyuki Nogami, Masahiro Tabata, Nagio Takigawa, Hiroshi Ueoka, Mitsune Tanimoto, Mine Harada

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The majority of patients with advanced lung cancer die within a few years. Accordingly, new therapeutic modalities need to be developed. Interleukin (IL)-12 was previously known as natural killer (NK) cell stimulatory factor or cytotoxic lymphocyte maturation factor. By virtue of its effects on T cells and NK cells, IL-12 seems to be one of the key cytokines that regulates cell-mediated anti tumor immune responses. Recently, there has been a substantial interest in the potential applications of IL-12 in the treatment of lung cancer. However, there have been no reports about the effect of IL-12 on peripheral blood mononuclear cells (PBMCs) obtained from lung cancer patients in an autologous setting. In this study, we examined the cytotoxicity of PBMC activated by IL-2, IL-12 or both against K562 or autologous lung cancer cells. In contrast to the effect of IL-2 on NK activity, IL-12 alone augmented NK activity against K562 cells, but not against autologous lung cancer cells. IL-12 augmented the IL-2 mediated cytotoxicity of PBMC against both K562 and autologous lung cancer cells. In the absence of IL-2, IL-12 alone cannot induce an autologous anti-tumor effect in vivo. In summary, our results clearly demonstrated that IL-12 can augment the cytolytic activity of PBMC against K562 and autologous lung cancer cells when combined with IL-2, although, IL-12 alone was unable to induce a marked increase in the cytotoxicity against autologous lung cancer cells. These results suggest that an administration of IL-12 in combination with IL-2 may be a useful therapeutic option for solid tumors.

Original languageEnglish
Pages (from-to)329-333
Number of pages5
JournalLung Cancer
Volume35
Issue number3
DOIs
Publication statusPublished - 2002

Fingerprint

Interleukin-12
Interleukin-2
Lung Neoplasms
Blood Cells
Neoplasms
K562 Cells
Natural Killer Cells
Therapeutics
Cytokines

Keywords

  • CTL
  • IL-12
  • IL-2
  • Immunotherapy
  • Lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2. / Hiraki, Akio; Kiura, Katsuyuki; Yamane, Hiromichi; Nogami, Naoyuki; Tabata, Masahiro; Takigawa, Nagio; Ueoka, Hiroshi; Tanimoto, Mitsune; Harada, Mine.

In: Lung Cancer, Vol. 35, No. 3, 2002, p. 329-333.

Research output: Contribution to journalArticle

Hiraki, Akio ; Kiura, Katsuyuki ; Yamane, Hiromichi ; Nogami, Naoyuki ; Tabata, Masahiro ; Takigawa, Nagio ; Ueoka, Hiroshi ; Tanimoto, Mitsune ; Harada, Mine. / Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2. In: Lung Cancer. 2002 ; Vol. 35, No. 3. pp. 329-333.
@article{dadab09f77374e2f9b24860c5cfc60ab,
title = "Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2",
abstract = "The majority of patients with advanced lung cancer die within a few years. Accordingly, new therapeutic modalities need to be developed. Interleukin (IL)-12 was previously known as natural killer (NK) cell stimulatory factor or cytotoxic lymphocyte maturation factor. By virtue of its effects on T cells and NK cells, IL-12 seems to be one of the key cytokines that regulates cell-mediated anti tumor immune responses. Recently, there has been a substantial interest in the potential applications of IL-12 in the treatment of lung cancer. However, there have been no reports about the effect of IL-12 on peripheral blood mononuclear cells (PBMCs) obtained from lung cancer patients in an autologous setting. In this study, we examined the cytotoxicity of PBMC activated by IL-2, IL-12 or both against K562 or autologous lung cancer cells. In contrast to the effect of IL-2 on NK activity, IL-12 alone augmented NK activity against K562 cells, but not against autologous lung cancer cells. IL-12 augmented the IL-2 mediated cytotoxicity of PBMC against both K562 and autologous lung cancer cells. In the absence of IL-2, IL-12 alone cannot induce an autologous anti-tumor effect in vivo. In summary, our results clearly demonstrated that IL-12 can augment the cytolytic activity of PBMC against K562 and autologous lung cancer cells when combined with IL-2, although, IL-12 alone was unable to induce a marked increase in the cytotoxicity against autologous lung cancer cells. These results suggest that an administration of IL-12 in combination with IL-2 may be a useful therapeutic option for solid tumors.",
keywords = "CTL, IL-12, IL-2, Immunotherapy, Lung cancer",
author = "Akio Hiraki and Katsuyuki Kiura and Hiromichi Yamane and Naoyuki Nogami and Masahiro Tabata and Nagio Takigawa and Hiroshi Ueoka and Mitsune Tanimoto and Mine Harada",
year = "2002",
doi = "10.1016/S0169-5002(01)00424-X",
language = "English",
volume = "35",
pages = "329--333",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2

AU - Hiraki, Akio

AU - Kiura, Katsuyuki

AU - Yamane, Hiromichi

AU - Nogami, Naoyuki

AU - Tabata, Masahiro

AU - Takigawa, Nagio

AU - Ueoka, Hiroshi

AU - Tanimoto, Mitsune

AU - Harada, Mine

PY - 2002

Y1 - 2002

N2 - The majority of patients with advanced lung cancer die within a few years. Accordingly, new therapeutic modalities need to be developed. Interleukin (IL)-12 was previously known as natural killer (NK) cell stimulatory factor or cytotoxic lymphocyte maturation factor. By virtue of its effects on T cells and NK cells, IL-12 seems to be one of the key cytokines that regulates cell-mediated anti tumor immune responses. Recently, there has been a substantial interest in the potential applications of IL-12 in the treatment of lung cancer. However, there have been no reports about the effect of IL-12 on peripheral blood mononuclear cells (PBMCs) obtained from lung cancer patients in an autologous setting. In this study, we examined the cytotoxicity of PBMC activated by IL-2, IL-12 or both against K562 or autologous lung cancer cells. In contrast to the effect of IL-2 on NK activity, IL-12 alone augmented NK activity against K562 cells, but not against autologous lung cancer cells. IL-12 augmented the IL-2 mediated cytotoxicity of PBMC against both K562 and autologous lung cancer cells. In the absence of IL-2, IL-12 alone cannot induce an autologous anti-tumor effect in vivo. In summary, our results clearly demonstrated that IL-12 can augment the cytolytic activity of PBMC against K562 and autologous lung cancer cells when combined with IL-2, although, IL-12 alone was unable to induce a marked increase in the cytotoxicity against autologous lung cancer cells. These results suggest that an administration of IL-12 in combination with IL-2 may be a useful therapeutic option for solid tumors.

AB - The majority of patients with advanced lung cancer die within a few years. Accordingly, new therapeutic modalities need to be developed. Interleukin (IL)-12 was previously known as natural killer (NK) cell stimulatory factor or cytotoxic lymphocyte maturation factor. By virtue of its effects on T cells and NK cells, IL-12 seems to be one of the key cytokines that regulates cell-mediated anti tumor immune responses. Recently, there has been a substantial interest in the potential applications of IL-12 in the treatment of lung cancer. However, there have been no reports about the effect of IL-12 on peripheral blood mononuclear cells (PBMCs) obtained from lung cancer patients in an autologous setting. In this study, we examined the cytotoxicity of PBMC activated by IL-2, IL-12 or both against K562 or autologous lung cancer cells. In contrast to the effect of IL-2 on NK activity, IL-12 alone augmented NK activity against K562 cells, but not against autologous lung cancer cells. IL-12 augmented the IL-2 mediated cytotoxicity of PBMC against both K562 and autologous lung cancer cells. In the absence of IL-2, IL-12 alone cannot induce an autologous anti-tumor effect in vivo. In summary, our results clearly demonstrated that IL-12 can augment the cytolytic activity of PBMC against K562 and autologous lung cancer cells when combined with IL-2, although, IL-12 alone was unable to induce a marked increase in the cytotoxicity against autologous lung cancer cells. These results suggest that an administration of IL-12 in combination with IL-2 may be a useful therapeutic option for solid tumors.

KW - CTL

KW - IL-12

KW - IL-2

KW - Immunotherapy

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0036181115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036181115&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(01)00424-X

DO - 10.1016/S0169-5002(01)00424-X

M3 - Article

C2 - 11844609

AN - SCOPUS:0036181115

VL - 35

SP - 329

EP - 333

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -